# Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve

> **NCT07117682** · NA · NOT_YET_RECRUITING · sponsor: **Cytori Therapeutics** · enrollment: 25 (estimated)

## Conditions studied

- Diminished Ovarian Reserve (DOR)
- Primary Ovarian Insufficiency (Poi)
- Ovarian Failure, Premature

## Interventions

- **DEVICE:** Autologous Adipose-Derived Regenerative Cells (ADRCs) Intraovarian Injection

## Key facts

- **NCT ID:** NCT07117682
- **Lead sponsor:** Cytori Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117682, "Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07117682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*